Across TCGA pan-cancer cohorts, PEF1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PEF1 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher PEF1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PEF1 expression acts as an unfavorable survival marker.
ESCA and PRAD are the cancer types where PEF1 Mutation most reproducibly stratifies survival.